Stem Cell Therapeutics Changes Its Name to Trillium Therapeutics Inc.

Stem Cell Therapeutics Corp. ("SCT") (TSX:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing innovative therapies for the treatment of cancer, today
announced that it has filed articles of amalgamation to merge with its
wholly-owned subsidiary Trillium Therapeutics Inc. ("TTI"). The combined company
has adopted the Trillium name. 


"The use of "Stem Cell" in our company name did not properly reflect our
business, which is strongly focused on the immuno-oncology area, such as our
checkpoint inhibitor program targeting the CD47/SIRPa immunoregulatory axis,"
commented Dr. Niclas Stiernholm, Chief Executive Officer. "Trillium enjoyed a
solid reputation in the biopharmaceutical industry for its high quality
immunotherapy research, exemplified by a decade of strong industry and academic
partnerships. We will clearly benefit from this brand recognition with our
return to the Trillium name." 


Conditional approval for the name change was received from the TSX. The Company
will soon begin trading under the symbol "TR".


About Trillium Therapeutics: 

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The Company has two premier preclinical
programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune
system. SIRPaFc is an antibody-like fusion protein that blocks the activity of
CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia
(AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal
antibody that blocks the activity of CD200, an immunosuppressive molecule that
is overexpressed by many hematopoietic and solid tumors. TTI's clinical stage
programs include tigecycline which is being evaluated in a multi-centre Phase I
study in patients with AML and TTI-1612, which has been tested in a 28-patient
Phase I trial in interstitial cystitis ("IC") patients. For more information,
visit: www.trilliumtherapeutics.com. 


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect TTI's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in TTI's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, TTI undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX nor its Regulation Services Provider (as that term is defined in the
policies of the TSX) accepts responsibility for the adequacy or accuracy of this
release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
[phone]
[e-mail]
www.trilliumtherapeutics.com